Skip to main content
. 2012 Dec 14;2(6):e001768. doi: 10.1136/bmjopen-2012-001768

Table 1.

Proportion of GPRD AF patients who met inclusion/exclusion criteria for RE-LY, ARISTOTLE and ROCKET-AF, stratified by risk of stroke and assessment method

Patient population Anticoagulant eligibility GPRD AF patient population, N (%) RE-LY
GPRD AF patients meeting trial criteria, n (% (95% CI))
ARISTOTLE
GPRD AF patients meeting trial criteria n (% (95% CI))
ROCKET-AF
GPRD AF patients meeting trial criteria, n (% (95% CI))
Total GPRD AF population Not anticoagulant-eligible/potentially anticoagulant-eligible/should receive anticoagulant according to guidelines 83 898 (100) 53 640 (64 (63.59 to 64.41)) 51 415 (61 (60.58 to 61.42)) 39 892 (48 (47.66 to 48.34))
Intermediate-risk or high-risk patients
CHADS2 ≥1 Potentially anticoagulant-eligible/should receive anticoagulant according to guidelines 71 493 (85) 52 783 (74 (73.68 to 74.32)) 51 415 (72 (71.67 to 72.33)) 39 892 (56 (55.64 to 56.36))
CHA2DS2-VASc ≥1 Potentially anticoagulant-eligible/should receive anticoagulant according to guidelines 78 783 (94) 53 640 (68 (67.67 to 68.33)) 51 163 (65 (64.67 to 65.33)) 39 892 (51 (50.65 to 51.35))
High-risk patients
CHADS2 ≥2 Should receive anticoagulant according to guidelines 49 099 (59) 38 493 (78 (77.63 to 78.37)) 35 712 (73 (72.61 to 73.39)) 39 892 (81 (80.65 to 81.35))
CHA2DS2-VASc ≥2 Should receive anticoagulant according to guidelines 72 824 (87) 53 059 (73 (72.68 to 73.32)) 50 623 (70 (69.67 to 70.33)) 39 835 (55 (54.64 to 55.36))

AF, atrial fibrillation; GPRD, General Practice Research Database.